Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-806-2 | CAS number: 110-82-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: other routes
Administrative data
- Endpoint:
- repeated dose toxicity: other route
- Remarks:
- other: I.P. injection 5 times/week for 2 weeks and time-course experiment for 10 consecutive days of i.p. injection
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Non-guideline study, GLP status unknown, published in peer reviewed literature but route of exposure (intra-peritoneal) not relevant for human exposures.
Data source
Reference
- Reference Type:
- publication
- Title:
- Evaluation of the subacute nephrotoxicity of cyclohexane and other industrial solvents in the female Sprague-Dawley rat
- Author:
- Bernard AM, de Russis R, Normand J, Lauwerys R
- Year:
- 1 989
- Bibliographic source:
- Toxicology Letters 45 (1989) 271-280
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Female Sprague-Dawley rats were injected i.p. with 1.5 or 1 g/kg cyclohexane, 5 times per week for 2 weeks and urinary excretion of ß2-microglobulin,albumin and N-acetyl-ß-glucosaminidase measured. In a time-course experiment, rats were injected for10 consecutive days with 0.375, 0.75 or 1.5 g/kg cyclohexane or 0.4 g/kg cyclohexanol, controls were injected with olive oil only (2.5 ml/kg). The urinary excretion of ß2-microglobulin, and the effects on effects on glomerular filtration rate, renal plasma flow, relative kidney weights and renal concentrating ability were assessed.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Cyclohexane
- EC Number:
- 203-806-2
- EC Name:
- Cyclohexane
- Cas Number:
- 110-82-7
- Molecular formula:
- C6H12
- IUPAC Name:
- cyclohexane
- Details on test material:
- analytical grade used
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 2-4 months
- Weight at study initiation: 150-250 g
- Fasting period before study:
- Diet: A.03 pellets (Usine d'alimentation ratiooelle, Epinay-sur-Orge, France) ad libitum (except during urine collection)
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature : 22°C
- Humidity : 65%
- Photoperiod: 12 hrs dark / 12 hrs light
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- olive oil
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 14 days
- Frequency of treatment:
- Injected i.p. 5 times per week for 2 weeks. In a time course experiment, injected daily for 10 consecutive days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Nominal 1.5 and 1.0 g/kg cyclohexane in olive oil (5 times per week for 2 weeks). In time course experiment, nominal 0.375, 0.75, 1.5 g/kg cyclohexane or 0.4 g/kg cyclohexanol in olive oil (daily for 10 consecutive days).
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Urine collection: After each series of 10 injections, a 24-hr urine collection was carried out by placing rats in individual stainless-steel metabolism cages equipped with urine/faeces separators. No food was given during urine collection but water was provided ad libitum. In the time-course experiment, a 24-h urine collection was carried out before the first injection, then every 2 days for 10 days. The collection flasks contained 10 mg of NaN3 as preservative.
Examinations
- Observations and examinations performed and frequency:
- The concentration of albumin and ß2-microglobulin in urine was determined using an automated immunoassay based on latex particle agglutination. The activity of N-acetyl-ß-glucosaminidase in was assayed using 4-methylumbelliferyl-N-acetyl-ß-D-glucosaminide as substrate. The renal plasma flow and the glomerular filtration rate were estimated simultaneously from the clearance of 125I-iodohippurate and 51Cr-EDTA respectively. Clearance was determined from a single timed blood sample collected 60 min after intravenous injection of the radioisotopes. By measuring the osmolality of urine collected over 8 h following a 24-h water deprivation period the kidney concentrating ability could be determined. The concentrations of cyclohexanol and cyclohexanone in rat urine were determined by gas chromatography.
- Statistics:
- Differences between groups assessed by one-way analysis of variance followed by Dunett's multiple comparison test (P < 0.05 statistically significant). If parameters not normally distributed , statistical analysis performed on log-transformed data and geometric means used to present the results.
Results and discussion
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Remarks:
- glomerular filtration rate, renal plasma flow or relative kidney weights
- Effect level:
- 1 500 mg/kg bw/day (nominal)
- Dose descriptor:
- other: excretion of ß2-microglobulin
- Effect level:
- 1 500 mg/kg bw/day (nominal)
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Following an i.p injection of 1.5 g/kg cyclohexane, the only significant effect observed was an increased urinary excretion of ß2-microglobulin in rats. There were no effects in glomerular filtration rate, renal plasma flow or relative kidney weights. The renal concentrating ability was significantly depressed in rats treated with 1.5 g/kg cyclohexane.
There were no significant effects at doses of 1 g/kg cyclohexane and lower.
Applicant's summary and conclusion
- Conclusions:
- Cyclohexane, administered to female Sprague-Dawley rats, caused tubular injury as shown by a statistically significant increase in ß2-microglobulinuria, which was both time and dose-dependent. It was not accompanied by changes in the glomerular filtration rate and the renal plasma flow, but at the highest dose (1.5 g/kg) the renal concentrating ability was depressed. These renal tubular effects can most likely be ascribed to cyclohexanol, the main metabolite of cyclohexane.
- Executive summary:
The subacute nephrotoxicity of cyclohexane was assessed following repeated i.p. injections to female Sprague-Dawley rats. Dose levels of 1.5 and 1 g/kg (administered 5 times per week for 2 weeks) were used in a sub-acute investigation, with 0.375, 0.75 and 1.5 g/kg (daily for 10 consecutive days) given in a time course study. There was a statistically significant increase in ß2-microglobulinuria, which was both time and dose-dependent. It was not accompanied by changes in the glomerular filtration rate and the renal plasma flow, but at the highest dose (1.5 g/kg) the renal concentrating ability was depressed. The authors believe that these renal tubular effects can most likely be ascribed to cyclohexanol, the main metabolite of cyclohexane.
This study used the i.p route and very high doses and the results, therefore, have limited relevance to real life exposures to man.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.